Published January 2011
| Version v1
Journal article
Areva: clinical trials for a new treatment to fight cancer
Creators
Description
Areva Med, the branch of Areva dedicated to nuclear medicine, has been agreed by the American Food and Drug Administration to begin the validation of a new treatment to fight cancer. This treatment is called alpha radio-immunotherapy and is based on the use of Pb212. The validation phase aims at testing its efficiency on patients and will start in 2011 and will last 2 years. Areva has developed a process to extract Pb212 from thorium coming from ancient industrial activities. (A.C.)
Additional details
Additional titles
- Original title (French)
- Areva: essais cliniques pour un nouveau traitement contre le cancer
Publishing Information
- Journal Title
- Revue Generale Nucleaire
- Journal Issue
- no.1
- Journal Page Range
- p. 12
- ISSN
- 0335-5004
- CODEN
- RGNUDJ
INIS
- Country of Publication
- France
- Country of Input or Organization
- France
- INIS RN
- 43001576
- Subject category
- S62: RADIOLOGY AND NUCLEAR MEDICINE;
- Descriptors DEI
- CLINICAL TRIALS; DIAGNOSTIC USES; LEAD 212; RADIOIMMUNOTHERAPY
- Descriptors DEC
- BETA DECAY RADIOISOTOPES; BETA-MINUS DECAY RADIOISOTOPES; EVEN-EVEN NUCLEI; HEAVY NUCLEI; HOURS LIVING RADIOISOTOPES; IMMUNOTHERAPY; ISOTOPES; LEAD ISOTOPES; MEDICINE; NUCLEAR MEDICINE; NUCLEI; RADIOISOTOPES; RADIOLOGY; RADIOTHERAPY; TESTING; THERAPY; USES